Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antimicrobial Resistance Pattern, Predisposing Factors, and Outcome of Serratia Infection in Patients Treated at a Secondary-Care Hospital in Oman: A 5-Year Retrospective Study.
Sannathimmappa MB, Nambiar V, Al Siyabi KHSH, Hussain AS, Shah YA, Marimuthu Y, Al-Maqbali S, Annamanedi M, Al-Risi ES, Aravindakshan R. Sannathimmappa MB, et al. Among authors: al risi es. Adv Biomed Res. 2024 Oct 28;13:101. doi: 10.4103/abr.abr_381_23. eCollection 2024. Adv Biomed Res. 2024. PMID: 39717260 Free PMC article.
Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial.
Livraghi L, Martella F, Ghilli M, Angiolini C, Magnanini S, Moretti E, Bengala C, Risi E, Molinara E, Pazzagli I, Malorni L, Donati S, Gabellini S, Martignetti A, Giannessi P, Sanna G, Barellini L, Biagioni C, Boni L, Bianchi S, Roncella M, Biganzoli L. Livraghi L, et al. Among authors: risi e. Eur J Cancer. 2024 Dec;213:115108. doi: 10.1016/j.ejca.2024.115108. Epub 2024 Oct 31. Eur J Cancer. 2024. PMID: 39522332 Free article.
Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients.
Valachis A, Biganzoli L, Christopoulou A, Fjermeros K, Fountzila E, Geisler J, Gomez-Bravo R, Karihtala P, Kosmidis P, Koutras A, Linardou H, Lindman H, Martínez-Ballestero I, Rodríguez AB, Meattini I, Munoz-Mateu M, Othman M, Psyrri A, Risi E, Schiza A, Spathas N, Utriainen M, Visani L, Ballesteros S, Basdekis I, Hay SD, Fotis T, Fricker S, de Graaf G, Jenset M, Kanters T, Lampropoulos K, Markou C, Mastoraki K, Nanou C, Reales Aviles JM, Santaholma M, Kosmidis T. Valachis A, et al. Among authors: risi e. Future Oncol. 2024;20(37):2937-2948. doi: 10.1080/14796694.2024.2413841. Epub 2024 Oct 21. Future Oncol. 2024. PMID: 39431459 Free PMC article. Clinical Trial.
55 results